Copeptin in Differentiation of Polyuria and Polydipsia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01056887 |
Recruitment Status :
Completed
First Posted : January 26, 2010
Last Update Posted : April 25, 2011
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The differential diagnosis of patients with polyuria/ polydipsia is often complex, but important for the therapeutic strategy.
Challenging is in particular the clinical differentiation between patients with a partial Diabetes insipidus centralis and patients with primary polydipsia as underlying disease, because both groups are associated with similar urinary osmolalities.
The determination of plasma arginine vasopressin is unusual in this context, since measurement of AVP is not reliably.
C-terminal ProVasopressin (copeptin) is secreted stoichiometrically with AVP from the neurohypophysis, but has a longer half life in the circulation, and is thus easier to measure.
Therefore, the investigators will analyze in that study the diagnostic utility of plasma copeptin in the differential diagnosis of polyuria and polydipsia.
Condition or disease |
---|
Polyuria Polydipsia |
Study Type : | Observational |
Estimated Enrollment : | 50 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Study Start Date : | March 2008 |
Actual Primary Completion Date : | November 2010 |
Actual Study Completion Date : | November 2010 |

Group/Cohort |
---|
Primary Polydip, D. insipidus |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients with polydipsia/ polyuria, with indication for performing a deprivation test
- > 18 years
Exclusion Criteria:
- dDAVP during the last 14d
- pregnancy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01056887
Germany | |
Univ Hospital Wuerzburg | |
Wuerzburg, Bavaria, Germany, 97080 |
Responsible Party: | Prof. Dr. med. Bruno Allolio, FDAAA |
ClinicalTrials.gov Identifier: | NCT01056887 |
Other Study ID Numbers: |
17121979 33/07 |
First Posted: | January 26, 2010 Key Record Dates |
Last Update Posted: | April 25, 2011 |
Last Verified: | November 2010 |
diabetes insipidus primary polydipsia copeptin Utility of plasma copeptin in differential diagnosis of polyuria/ polydipsia while performing a traditional deprivation test |
Polyuria Polydipsia Urination Disorders |
Urologic Diseases Urological Manifestations Pathologic Processes |